|
Clinical Research – Loyola University Medical Center
|
|
TITLE
|
SPONSOR
|
PI
|
|
A Phase 3 Prospective, Randomized, Multi-Center, Open-Label, Controlled Trial to Assess the Efficacy and Safety of Cellular Immunotherapy with MDR-101 for Induction of Immune Tolerance in Recipients of HLA-Matched, Living Donor Kidney Transplants
|
Medeor Therapeutics
|
Akkina
|
|
The PROspera Kidney Transplant ACTIVE Rejection Assessment registry (ProActive) study
|
Natera
|
Akkina
|
|
REGISTRATION: SMART IRB: APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)
|
NIH/Wake Forest University Health Sciences
|
Jain
|
|
OUTCOMES OF KIDNEYCARE ON RENAL ALLOGRAFTS (OKRA)
|
CareDx
|
Jain
|
|
TruGraf® Long-term Clinical Outcomes Study (TRULO Study)
|
Transplant Genomics, Inc.
|
Sodhi
|
|
The PROspera Kidney Transplant ACTIVE Rejection Assessment (ProActive) Ancillary Study and Sample Biobank
|
Natera
|
Akkina
|
|
FALCON (402-C-1808) A PHASE 3 TRIAL OF THE EFFICACY AND SAFETY OF BARDOXOLONE METHYL IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE
|
Reata Pharmaceuticals
|
Vellanki
|
|
A PHASE III, RANDOMIZED, OPEN-LABEL ACTIVE COMPARATOR CONTROLLED MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF OBINUTUZUMAB IN PATIENTS WITH PRIMARY MEMBRANOUS NEPHROPATHY
|
Roche Pharmaceuticals
|
Kramer
|
|
Efficacy and safety of GMRx2 (a single pill combination containing telmisartan/amlodipine/indapamide) compared to dual combinations for the treatment of hypertension: An international, multi-center, randomized, double-blind, active-controlled, parallel-group trial (GMHT305 PLACEBO Trial)
|
George Health
|
Kramer
|
|
COMPLETED - PENDING CLOSE OUT – Loyola University Medical Center
|
|
Use of dd-cfDNA in Multi-Organ Transplant Rejection Detection (MOTR)
|
Natera
|
Akkina
|
|
Evaluation of patient outcomes from the kidney allograft outcomes allosure registry (KOAR)
|
CareDx
|
Jain
|
|
ICON Study 4690/0002, AlloVir Phase 2 Study in Patients with BK Viremia in Kidney Transplant Recipients 07/09/2021, NEW TITLE: : Phase 2 multicenter, randomized, double-blind, placebo-controlled, multiple dosing interval, 3-period study of the safety, tolerability and effectiveness of adoptively transferred ALVR105 (Viralym-M) multivirus-specific T cells in kidney transplant recipients with either high or low levels of BK viremia (P-105-201)
|
Icon
|
Jain
|
|
Prognostic Ability of dd-cfDNA in Renal Allograft Patients with COVID-19
|
PI initiated
|
Akkina
|